149003-01-0

149003-01-0 structure

Name: Dexrazoxane HCl (ICRF-187, ADR-529)
Chemical Name: dexrazoxane hydrochloride
CAS Number: 149003-01-0
Molecular Formula: C₁₁H₁₇ClN₄O₄
Molecular Weight: 304.73000
Catalog: Research Areas Cardiovascular Disease
Create Date: 2018-07-11 18:13:39
Modify Date: 2024-01-05 20:56:11
Dexrazoxane Hcl( ICRF-187 Hcl) is a cardioprotective agent. IC50 value:Target: cardioprotective agentAs a derivative of EDTA, dexrazoxane chelates iron, thus reduce the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. This agent is used to protect the heart against the cardiotoxic side effects of anthracyclines, such as doxorubicin. It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs.

Name	dexrazoxane hydrochloride
Synonyms	2,6-Piperazinedione, 4-[(1S)-2-(3,5-dioxo-1-piperazinyl)-1-methylethyl]-, hydrochloride (1:1) 4,4'-(2S)-Propan-1,2-diyldipiperazin-2,6-dionhydrochlorid 4,4'-(2S)-propane-1,2-diyldipipérazine-2,6-dione chlorhydrate (S)-4,4'-(1-Methyl-1,2-ethanediyl)bis-2,6-piperazinedionehydrochloride Dexrazoxane hydrochloride 2,6-Piperazinedione, 4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-, hydrochloride (1:1) 4,4'-[(2S)-1,2-Propanediyl]di(2,6-piperazinedione) hydrochloride (1:1) 2,6-piperazinedione, 4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-, monohydrochloride 4,4'-(2S)-Propane-1,2-diyldipiperazine-2,6-dione hydrochloride (1:1) Dexrazoxane HCl UNII:5346058Q7S Dexrazoxane (Hydrochloride)

Description	Dexrazoxane Hcl( ICRF-187 Hcl) is a cardioprotective agent. IC50 value:Target: cardioprotective agentAs a derivative of EDTA, dexrazoxane chelates iron, thus reduce the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. This agent is used to protect the heart against the cardiotoxic side effects of anthracyclines, such as doxorubicin. It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs.
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Cardiovascular Disease
References	[1]. Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs. 2008 Feb;17(2):217-23. [2]. Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. [3]. Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 201

Hazard Codes	Xi